Person:
ŞAHİN, AHMET BİLGEHAN

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

ŞAHİN

First Name

AHMET BİLGEHAN

Name

Search Results

Now showing 1 - 10 of 17
  • Publication
    Prognostic value of estrogen receptors in patients who underwent prostatectomy for non-metastatic prostate cancer
    (Spandidos Publ Ltd, 2023-02-01) Aydın, Yavuz Mert; Şahin, Ahmet Bilgehan; Dölek, Rabia; Vuruşkan, Berna Aytaç; Ocakoğlu, Gökhan; Vuruşkan, Hakan; Yavaşçaoğlu, İsmet; Coşkun, Burhan; AYDIN, YAVUZ MERT; ŞAHİN, AHMET BİLGEHAN; DÖLEK, RABİA; AYTAÇ VURUŞKAN, BERNA; OCAKOĞLU, GÖKHAN; VURUŞKAN, HAKAN; YAVAŞCAOĞLU, İSMET; COŞKUN, BURHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0002-6287-6767; 0000-0002-7846-0870; 0000-0002-1114-6051; 0000-0002-8242-9921; AAH-9704-2021; AFP-3055-2022; HSH-9815-2023; JCO-5169-2023; AAH-5180-2021; AAM-4927-2020; EEJ-1452-2022; EFH-9523-2022; EIN-0828-2022
    Estrogen receptors in prostate cancer (PCa) are a subject of debate. The aim of the present study was to investigate whether estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta) impact the biochemical recurrence (BCR) of non-metastatic PCa after surgery. Following the application of the exclusion criteria, data from 108 patients who underwent laparoscopic radical prostatectomy between January 2011 and December 2019 were retrospectively evaluated. A total of 36 patients with BCR constituted the BCR group. The control group was formed using the Propensity Score Matching (PSM) method with a 1:2 ratio, including parameters with well-studied effects on BCR. The median follow-up time was 74.3 (range, 30-127.5) months in the BCR group and 66.6 (range, 31.5-130) months in the control group. Pathology specimens from the two groups were immunohistochemically stained with ER alpha and ER beta antibodies. Logistic regression analysis and survival analysis were performed. No differences in clinicopathological characteristics were detected between the two groups. The patients with ER alpha(-)/ER beta(+) staining results had a significantly fewer BCRs than other patients (P=0.024). In the logistic regression analysis, patients with ER alpha(-)/ER beta(+) PCa also had a significantly lower risk of recurrence (P=0.048). In the survival analysis, the 5-year BCR-free survival rate of patients with ER alpha(-)/ER beta(+) PCa was higher than that of other patients (85.7 vs. 66.1%; P=0.031). Excluding the effects of well-studied risk factors for recurrence by the PSM method, the present study showed that ER alpha and ER beta have prognostic value for non-metastatic PCa. The 5-year BCR-free survival rate is significantly higher in patients whose PCa tissue has ER alpha(-)/ER beta(+) staining results.
  • Publication
    Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group
    (Springer, 2021-01-24) Gürbüz, Mustafa; Akkuş, Erman; Sakin, Abdullah; Urvay, Semiha; Demiray, Atike Gökçen; Şahin, Süleyman; Sakalar, Teoman; Erol, Cihan; Şendur, Mehmet Ali Nahit; Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Guven, Deniz Can; Kılıçkap, Saadettin; Ergün, Yakup; Uncu, Doğan; Turhal, Nazim Serdar; Uskent, Necdet; Çınkır, Havva Yeşil; Demir, Atakan; Acar, Ramazan; Karadurmuş, Nuri; Türker, Sema; Altınbaş, Mustafa; Karaoğlan, Mert; Şenler, Filiz Çay; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-7846-0870 ; 0000-0002-0070-0889; AAM-4927-2020 ; JGT-4101-2023
    Purpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab +/- capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab +/- capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance +/- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.
  • Publication
    The relationship between formal education level and delay in diagnosis and disease activity in patients with rheumatoid arthritis
    (BMJ Publishing Group, 2015-06-01) Öksüz, Mustafa Ferhat; YıIdırım, F.; Şahin, Bilgehan Ahmet; Göçken, Abdulkadir; Tufan, Ayşe Nur; Oruçoğlu, Nurdan; Dalkılıç, Ediz; Pehlivan, Yavuz; Öksüz, Mustafa Ferhat; YıIdırım, F.; ŞAHİN, AHMET BİLGEHAN; Göçken, Abdulkadir; Tufan, Ayşe Nur; Oruçoğlu, Nurdan; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-7846-0870; 0000-0002-8613-5373; D-2589-2017; AAM-4927-2020; AAG-8227-2021; JXF-7598-2024; EHU-6506-2022; CQX-7131-2022; GHE-4236-2022; CMF-4757-2022
  • Publication
    The predictive importance of body-mass index on response to neoadjuvant chemotherapy in patients with breast cancer
    (Karger, 2022-09-14) Emirzeoğlu, Levent; Arıcı, Serdar; Şahin, Ahmet Bilgehan; Ocak, Birol; Ak, Naziye; Ay, Seval; Mammadov, Elkhan; Turna, Hande; Bilici, Ahmet; ŞAHİN, AHMET BİLGEHAN; OCAK, BİROL; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı; 0000-0002-7846-0870; 0000-0001-7537-1699; LLD-9901-2024; AAM-4927-2020
    Purpose: To investigate the effects of body mass index (BMI) on the response to neoadjuvant chemotherapy (NACT) in Turkish patients with local and locally advanced breast cancer.Methods: The pathological responses for the breast and axilla were assessed according to the Miller-Payne grading (MPG) system. Tumors were grouped into molecular phenotypes and classified as response rates according to the MPG system after completion of NACT. A 90% or greater reduction in tumor cellularity was considered as good response to treatment. Additionally, patients were grouped according to BMI into <25 (group A) and >= 25 (group B).Results: In total, 647 Turkish women with breast cancer were included in the study. In the univariate analysis, age, menopause status, tumor diameter, stage, histological grade, Ki-67, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, and BMI were assessed to determine which of these factors were associated with a >= 90% response rate. Stage, HER2 positivity, triple-negative breast cancer (TNBC; ER-negative, PR-negative, and HER2 negative breast cancer), grade, Ki67 levels, and BMI were found to be the statistically significant factors for a >= 90% response rate. In the multivariate analysis, grade III disease, HER2 positivity, and TNBC were found to be the factors associated with a high pathological response. Meanwhile, hormone receptor (HR) positivity and a higher BMI were associated with a decreased pathologic response in patients receiving NACT for breast cancer.Conclusion: Our results show that a high BMI and HR positivity are associated with a poor response to neoadjuvant chemotherapy in Turkish patients with breast cancer. The findings presented in this study may guide novel studies to examine the NACT response in obese patients with and without insulin resistance.
  • Publication
    Relationship between carotid intima-media thickness and proteinuria in patients with metabolic syndrome
    (Aves, 2014-12-01) Ayar, Yavuz; Atalay, Hande; Boyuk, Banu; Sayılar, Emel Işıktaş; Şahin, Ahmet Bilgehan; Gömleksiz, Muhammet Rıdvan; Karaduman, Rıza; Çelebi, Aslan; Ayar, Yavuz; Sayılar, Emel Işıktaş; ŞAHİN, AHMET BİLGEHAN; Gömleksiz, Muhammet Rıdvan; Karaduman, Rıza; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 000-0003-4607-9220; 0000-0002-7846-0870; 0000-0001-5434-8924; AGF-0767-2022; W-2575-2017; AAM-4927-2020; ABG-3512-2021; FDT-3405-2022
    Objective: This study aimed to find the relationship between intima-media thickness and proteinuria, which are early findings of atherosclerosis and renal failure in patients with metabolic syndrome.Methods: In our study, 63 patients with metabolic syndrome and 26 healthy subjects, as the control group, were involved. Both groups were over 40 years old in the study. In both groups, carotid intima-media thickness was measured with B-mode ultrasonography. All biochemical data were analyzed retrospectively.Results: Overall, 61.9% of patients were women; 38.1% of them were men. Also, 61.54% of the control group was female; 38.46% of them were men. Carotid intima-media thickness, level of glucose, urea, creatinine, high-density lipoprotein (HDL) cholesterol, uric acid, C-reactive protein (CRP), retinopathy (p<0.001), age (p=0.017), triglyceride (p=0.022), glomerular filtration rate (GFR) (p=0.029), proteinuria (p=0.035), abdominal circumference (p=0.006), body mass index (BMI) (p=0.047), and thyroid-stimulating hormone (TSH) (p=0.013) were significantly higher in patients with metabolic syndrome.Conclusion: In the patients with metabolic syndrome, carotid intima-media thickness and proteinuria are precursors of atherosclerosis. These findings are important predictions for the development of type II diabetes mellitus, coronary heart disease, and chronic kidney disease.
  • Publication
    Efficacy and safety of trastuzumab emtansine in her2 positive metastatic breast cancer: Real-world experience
    (Taylor & Francis, 2021-06-05) Bahçeci, Aykut; Paydaş, Semra; Ak, Naziye; Ferhatoğlu, Ferhat; Saip, Pınar Mualla; Şeydaoğlu, Gülşah; Bilici, Mehmet; Şimşek, Melih; Tekin, Salim Başol; Çalıkuşu, Züleyha; Yavuz, Sinan; Şahin, Ahmet Bilgehan; Çubukcu, Erdem; Evrensel, Türkkan; Değirmencioğlu, Serkan; Demiray, Atike Gökçen; Yumuk, Perran Fulden; Alan, Özkan; Çıkman, Duygu İlke; Demirelli, Fuat Hulusi; Köstek, Osman; Gökyer, Ali; Doğan, Mutlu; Bal, Öznur; Çakar, Burcu; Gökmen, Erhan; Yamaç, Deniz; Korkmaz, Taner; Aliyev, Altay; Keskin, Özge; Urvay, Semiha; Buyukşimşek, Mahmut; Karadeniz, Cemile; Yıldız, Birol; Çınkır, Havva Yeşil; Demir, Hacer; Beypınar, İsmail; Karacin, Cengiz; Eser, Kadir; Baykara, Meltem; Kılıçkap, Saadettin; Okutur, Kerem; Bulut, Gülcan; Alkan, Ali; Arpacı, Erkan; Pilancı, Kezban Nur; Demir, Atakan; Işık, Deniz; Yıldırım, Nilgün; ŞAHİN, AHMET BİLGEHAN; ÇUBUKÇU, ERDEM; EVRENSEL, TÜRKKAN; 0000-0002-7846-0870 ; AAM-4927-2020; JGT-4101-2023 ; EXZ-0745-2022
    Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.
  • Publication
    Focal segmental glomerulosclerosis: A single center experience
    (Galenos Yayıncılık, 2016-09-01) Ayar, Yavuz; Ersoy, Alparslan; Yıldız, Abdülmecit; Oruç, Ayşegül; Can, Fatma Ezgi; Ocakoğlu, Gökhan; Güllülü, Mustafa; Demirayak, Dilay; Bayrakçı, İsmail; Düger, Hakan; Ocak, Tuğba; Korkut, Bayram; Şahin, Ahmet Bilgehan; Akan, Mustafa; Eylemer, Eda; Ayar, Yavuz; ERSOY, ALPARSLAN; YILDIZ, ABDULMECİT; ORUÇ, AYŞEGÜL; Can, Fatma Ezgi; OCAKOĞLU, GÖKHAN; GÜLLÜLÜ, MUSTAFA; Demirayak, Dilay; Bayrakçı, İsmail; Düger, Hakan; OCAK, TUĞBA; Korkut, Bayram; ŞAHİN, AHMET BİLGEHAN; Akan, Mustafa; Eylemer, Eda; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-4607-9220; 0000-0002-0342-9692; 0000-0002-1114-6051; 0000-0001-5926-6813; 0000-0001-5478-3192; 0000-0002-7846-0870; 0000-0002-9252-8341; 0000-0002-0710-0923; 0000-0002-1953-7735; AGF-0767-2022; AAH-5054-2021; HIG-9032-2022; AAH-4002-2021; JSL-7718-2023; HLG-6346-2023; JGS-9425-2023; EQO-1344-2022; JLB-1564-2023; IZP-9361-2023; FPM-3131-2022; FFH-4157-2022; AAM-4927-2020; KUI-8062-2024; COF-1782-2022
    Aim: Focal segmental glomerulosclerosis (FSGS) is one of the most common glomerulonephritis (GNP) worldwide. Despite treatment, it may progress to end-stage renal disease. In the present study, we compared clinical and histopathological data on FSGS with primary and secondary GNP retrospectively.Methods: We retrospectively analyzed data on clinical and laboratory findings, treatment response, and risk factors associated with mortality in patients, who had been diagnosed with FSGS and other GNP via renal biopsy between January 2009 and December 2014. The average follow-up time was 22 (8-76) months.Results: FSGS and primary GNP were more frequently seen in males than in females (55.9% vs. 65.3%, p=0.033). Nephrotic syndrome was more common in patients with FSGS (41.2%) and primary GNP (57.7%), while chronic renal disease was more frequent in patients with secondary GNP (35%). In FSGS, the complete remission rate was 54.4%. 63.2% of patients had continued to receive treatment. According to the biopsy findings, interstitial inflammation and fibrosis were observed in 100% and 98.5% of patients with FSGS, respectively (p=0.010 and p<0.001, respectively). Serum albumin level was found to be increased and proteinuria, total cholesterol, triglyceride, and LDL levels to be decreased after treatment (p<0.001). Serum creatinine levels and type of GNP (secondary GNP) were detected to be 1.48 and 8.14 fold increased in mortality analysis, respectively.Conclusion: Renal biopsy is the gold standard for the diagnosis of glomerular diseases. Renal function at the time of diagnosis, follow-up and appropriate immunosuppressive therapy have effects on mortality and clinical progress in FSGS as is the case in all GNPs.
  • Publication
    Efficacy of chemotherapeutics on classic and non-classic kaposi sarcoma: A single-center retrospective real-world study
    (Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2021-01-01) Orhan, Sibel Oyucu; OYUCU ORHAN, SİBEL; Sahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Çubukcu, Erdem; ÇUBUKÇU, ERDEM; Deligonul, Adem; DELİGÖNÜL, ADEM; Ocak, Birol; OCAK, BİROL; Orhan, Bedrettin; ORHAN, BEDRETTİN; Evrensel, Turkkan; EVRENSEL, TÜRKKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0002-7846-0870; 0000-0001-7537-1699; ACW-2157-2022; AAJ-8314-2021; AEC-2238-2022; AAM-4927-2020
    Kaposi sarcoma (KS) is a rare disease, and especially for classic KS, a gap exists in the literature about which chemotherapeutics should be given. Here we present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 patients with KS treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics of and the chemotherapeutic agents administered to the 16 patients with KS diagnosed in our center based on the medical records obtained. The median age, gender, KS type, involved site, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4-85.8 years). Among the patients, one had immunosuppression-related KS, four had acquired immune deficiency syndrome-related KS, and 11 had classic KS. Regarding the first-line cytotoxic therapy, seven patients received pegylated liposomal doxorubicin (PLD), six received paclitaxel, two received oral etoposide, and one received the doxorubicin, bleomycin, and vincristine regimen. The Kaplan-Meier analysis showed that the PFS was 39.9 months (95% confidence interval (CI), 7.7-72.0). In the first-line setting, a significant difference in PFS was observed between the PLD-and paclitaxel-treated groups (unreached vs. 12.8 months; p = 0.033). The OS was 66.1 months (95% CI, 30.2-102.0). The ORR and DCR of the 16 patients were 43.8%, and 81.3%, respectively. No grade 3 or 4 toxicity was observed. This retrospective study showed that among the most preferred chemotherapeutic agents, PLD seems better than paclitaxel in terms of PFS and response rates, and it showed a good safety profile in patients with KS.
  • Publication
    The impact of ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer
    (Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2021-01-01) Ocak, Birol; Atalay, Fatma Oz; Sahin, Ahmet Bilgehan; Ozsen, Mine; Dakiki, Bahar; Ture, Seray; Mesohorli, Merve; Odman, Hikmet Utku; Tanriverdi, Ozgur; Ocakoglu, Gokhan; Bayrak, Mehmet; Ozan, Hakan; Demiroz, Candan; Sali, Seda; Orhan, Sibel Oyucu; Deligönül, Adem; Çubukcu, Erdem; Evrensel, Turkkan; Ocak, Birol; OCAK, BİROL; Sahin, Ahmet Bilgehan; ŞAHİN, AHMET BİLGEHAN; Atalay, Fatma Oz; ÖZ ATALAY, FATMA; Ozsen, Mine; ÖZŞEN, MİNE; Dakiki, Bahar; DAKİKİ KORUCU, BAHAR; Ture, Seray; TÜRE AYDIN, SERAY; Mesohorli, Merve; Odman, Hikmet Utku; Ocakoglu, Gokhan; OCAKOĞLU, GÖKHAN; Bayrak, Mehmet; Ozan, Hakan; OZAN, HAKAN; Demiroz, Candan; DEMİRÖZ ABAKAY, CANDAN; Sali, Seda; SALİ, SEDA; Orhan, Sibel Oyucu; OYUCU ORHAN, SİBEL; Deligonul, Adem; DELİGÖNÜL, ADEM; Cubukcu, Erdem; ÇUBUKÇU, ERDEM; Evrensel, Turkkan; EVRENSEL, TÜRKKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0001-7537-1699; 0000-0002-7188-6115; 0000-0002-7846-0870; 0000-0002-5771-7649; 0000-0001-9255-2475; 0000-0002-1114-6051; 0000-0003-1600-333X; AEC-2238-2022; ABA-2897-2021; AAH-5180-2021; AAM-4927-2020; AAJ-8314-2021
    Endometrial endometrioid carcinoma (EEC) represents approximately 75-80% of endometrial carcinoma cases. Three hundred and thirty-six patients with EEC followed-up in the authors' medical center between 2010 and 2018 were included in our study. Two hundred and seventy-two low and intermediate EEC patients were identified using the European Society for Medical Oncology criteria and confirmed by histopathological examination. Recurrence was reported in 17 of these patients. The study group consisted of patients with relapse. A control group of 51 patients was formed at a ratio of 3:1 according to age, stage, and grade, similar to that in the study group. Of the 17 patients with recurrent disease, 13 patients (76.5%) were Stage 1A, and 4 patients (23.5%) were Stage 1B. No significant difference was found in age, stage, and grade between the case and control groups (p > 0.05). Body mass index, parity, tumor size, lower uterine segment involvement, squamous differentiation (SqD), and Ki-67 index with p<0.25 in the univariate logistic regression analysis were included in the multivariate analysis. Ki-67 was statistically significant in multivariate analysis (p = 0.018); however, there was no statistical significance in SqD and other parameters. Our data suggest that the Ki-67 index rather than SqD needs to be assessed for recurrence in patients with low- and intermediate-risk EEC.
  • Publication
    Factors influencing lymphocele development after kidney transplant: Single center experience
    (Başkent Üniversitesi, 2023-03-01) Sayılar, Emel Işıktaş; Ersoy, Alparslan; Ayar, Yavuz; Aydın, Mehmet Fethullah; Şahin, Ahmet Bilgehan; Coşkun, Burhan; Kaygısız, Onur; Yıldız, Abdülmecit; Kordan, Yakup; Vuruşkan, Hakan; Sayılar, Emel Işıktaş; ERSOY, ALPARSLAN; Ayar, Yavuz; Aydın, Mehmet Fethullah; ŞAHİN, AHMET BİLGEHAN; COŞKUN, BURHAN; KAYGISIZ, ONUR; YILDIZ, ABDULMECİT; Kordan, Yakup; VURUŞKAN, HAKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; 0000-0003-4607-9220; 0000-0002-5665-7402; 0000-0002-7846-0870; 0000-0002-8242-9921; 0000-0002-9790-7295; 0000-0002-9947-848X; AAJ-8220-2020; O-9948-2015; AAH-9704-2021; L-9439-2019; JCO-5169-2023; AAM-4927-2020; HYA-4372-2023; CPX-5894-2022; HIG-9032-2022; GAF-0095-2022; EFH-9523-2022
    Objectives: Lymphocele is a well-known postoperative surgical complication after kidney transplant. In this study, our aim was to analyze incidence, risk factors, and outcomes of posttransplant lymphocele in a large cohort.Materials and Methods: This observational study included 395 consecutive patients (219 males and 176 females) who underwent kidney transplant procedures from 183 living and 212 deceased donors in our center between January 2007 and 2014. A lymphocele was diagnosed with ultrasonography.Results: The incidence of lymphoceles in our cohort was 31.9% (n = 126). There were no significant differences with regard to body mass indexes, age of donors, deceased donor ratios, acute rejection episodes, and history of abdominal surgery between those with and without lymphoceles. The pretransplant serum albumin levels (3.29 +/- 0.67 vs 3.48 +/- 0.69 g/dL; P = .009) in the lymphocele group and diabetes mellitus ratios (15.9% vs 4.5%; P < .001) in the nonlymphocele group were lower than levels shown in the other group. The lymphocele ratio in patients who received cyclosporine was higher than that shown in patients who did not received it (37.5% vs. 27.4%; P = .032). There was no difference in lymphocele incidence between patients who were taking and those who were not taking mammalian target of rapamycin inhibitors, mycophenolate mofetil, or mycophenolate sodium. In regression analysis, presence of diabetes mellitus, transplant from deceased donors, older age of donors, and lower albumin levels were independent risk factors for posttransplant lymphocele occurrence.Conclusions: Posttransplant lymphocele was a relatively common surgical complication in our cohort. We concluded that diabetes mellitus, use of kidneys from deceased donors, older donor age, and hypoalbuminemia were independent risk factors for lymphocele development.